Biocorrx (OTCMKTS:BICX) Issues Quarterly Earnings Results, Beats Expectations By $0.11 EPS

Biocorrx (OTCMKTS:BICX) announced its earnings results on Tuesday. The company reported $0.05 EPS for the quarter, beating the consensus estimate of ($0.06) by $0.11, Zacks reports. The company had revenue of ($0.15) million during the quarter, compared to the consensus estimate of $0.22 million.

Biocorrx Stock Performance

Shares of OTCMKTS BICX remained flat at $0.40 during midday trading on Wednesday. 200 shares of the stock were exchanged, compared to its average volume of 1,219. The company has a market cap of $10.56 million, a price-to-earnings ratio of -1.25 and a beta of 0.33. Biocorrx has a 1 year low of $0.20 and a 1 year high of $0.50. The firm has a fifty day simple moving average of $0.35 and a 200 day simple moving average of $0.36.

Biocorrx Company Profile

BioCorRx Inc, through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders in the United States. It distributes and licenses BioCorRx recovery program, a non-addictive and medication-assisted treatment program that includes a counseling program coupled with its proprietary naltrexone implant; and distributes UnCraveRx weight loss management program, a medically assisted weight management program to reduce food cravings combined with on-demand virtual lifestyle support, fitness, and nutrition.